Charles G. Drake
Immunology · 2004–2018
A researcher in the Science corpus: 17 papers; trusts 7 researchers and is trusted by 5 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 242 citations into it; #877 of 2,160 by trust here, #113 by citations
- Oncology — 199 citations into it; #650 of 1,698 by trust here, #81 by citations
Whom Charles G. Drake trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Charles G. Drake overall
Papers from Charles G. Drake's perspective
Ordered by how strongly the researchers Charles G. Drake trusts endorse each paper. Same corpus, a different order for every researcher.
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
- Restoring function in exhausted CD8 T cells during chronic viral infection (Nature)
- SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 (Journal of Immunology)
- Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (Cancer Research)
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome (Science)
- Coregulation of CD8+ T cell exhaustion during chronic viral infection by multiple inhibitory receptors (Nature Immunology)
- The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice (Journal of Experimental Medicine)
- Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival (Nature Medicine)
Their papers
- A draft map of the human proteome (2014) — 2,153 citations
- Inflammation in prostate carcinogenesis (2007) — 1,697 citations
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma (2018) — 1,088 citations
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017) — 630 citations
- LAG3 (CD223) as a Cancer Immunotherapy Target (2017) — 854 citations
- Immune checkpoint blockade: a common denominator approach to cancer therapy (2015) — 3,868 citations
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. (2015) — 812 citations
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Anti-Tumor Immune Responses via Cross-Presentation of Tumor Antigen (2014) — 614 citations
- Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma (2013) — 738 citations
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas (2013) — 859 citations
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012) — 7,418 citations
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity (2012) — 1,310 citations
- The composition and signaling of the IL-35 receptor are unconventional (2012) — 432 citations
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010) — 2,866 citations
- Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1 (2007) — 621 citations
- Mechanisms of immune evasion by tumors. (2006) — 690 citations
- Role of LAG-3 in regulatory T cells. (2004) — 1,284 citations